Administered paricalcitol dose and survival in hemodialysis patients: A marginal structural model analysis

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 11, 2012, Pages 1232-1239

  Miller, Jessica E ^a   Molnar, Miklos Z ^a,b,c   Kovesdy, Csaba P ^d,e   Zaritsky, Joshua J ^f   Streja, Elani ^a   Salusky, Isidro ^f   Arah, Onyebuchi A ^g   Kalantar Zadeh, Kamyar ^a,h  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic kidney disease; Marginal structural model; Mineral and bone disorders; Mortality; Paricalcitol; Pharmacoepidemiology; Propensity score

Indexed keywords

PARICALCITOL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL;

AGED; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, STRUCTURAL; MORTALITY; PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CALCITRIOL; RENAL DIALYSIS; SURVIVAL ANALYSIS;

EID: 84868203332     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3349     Document Type: Article

References (50)

1. Moe SM, Drueke T, Lameire N, et al. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis 2007; 14: 3-12.
2. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
3. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
4. Ambrus C, Molnar MZ, Czira ME, et al. Calcium, phosphate and parathyroid metabolism in kidney transplanted patients. Int Urol Nephrol 2009; 41: 1029-1038. 10.1007/s11255-009-9631-0.
5. Ambrus C, Almasi C, Berta K, et al. Bone mineral density and parathyroid function in patients on maintenance hemodialysis. Int Urol Nephrol 2011; 43: 191-201. 10.1007/s11255-009-9702-2.
6. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
7. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
8. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357.
9. Hernandez JD, Wesseling K, Salusky IB. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin Dial 2005; 18: 290-295.
10. Brown AJ, Slatopolsky E. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab 2007; 3: 134-144.
11. Thadhani R, Wolf M. Vitamin D in patients with kidney disease: cautiously optimistic. Adv Chronic Kidney Dis 2007; 14: 22-26.
12. Shinaberger CS, Kopple JD, Kovesdy CP, et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1769-1776.
13. Miller JE, Kovesdy CP, Norris KC, et al. Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Am J Nephrol 2010a; 32: 403-413.
14. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008; 73: 1355-1363.
15. Covic A, Apetrii M. Vitamin D receptor activation: clinical outcomes. Contrib Nephrol 2011; 171: 166-171.
16. Palmer SC, McGregor DO, Macaskill P, et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840-853.
17. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403.
18. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin d and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
19. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
20. Lee GH, Benner D, Regidor DL, et al. Impact of Kidney Bone Disease and Its Management on Survival of Patients on Dialysis. J Ren Nutr 2007; 17: 38-44.
21. Kalantar-Zadeh K, Miller JE, Kovesdy CP, et al. Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. J Bone Miner Res 2010a; 25: 2448-2458.
22. Wolf M, Betancourt J, Chang Y, et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19: 1379-1388.
23. Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med 1965; 58: 295-300.
24. Rosenbaum RP, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
25. Tentori F, Albert JM, Young EW, et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963-972.
26. Molnar MZ, Lukowsky LR, Streja E, et al. Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease. J Hypertens 2010; 28: 2475-2484.
27. Miller JE, Kovesdy CP, Nissenson AR, et al. Association of hemodialysis treatment time and dose with mortality and the role of race and sex. Am J Kidney Dis 2010b; 55: 100-112.
28. Kalantar-Zadeh K, Streja E, Kovesdy CP, et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 2010b; 85: 991-1001.
29. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1-201.
30. Kovesdy CP, Kalantar-Zadeh K. Observational studies vs Randomized controlled trial: Avenues to causal inference in nephrology. Adv Chronic Kidney Dis 2012; 19(1): 11-18.
31. Robins JM. Correction for non-compliance in equivalence trials. Stat Med 1998; 17: 269-302; discussion 387-269.
32. Robins JM. Marginal structural models versus structural nested models as tools for causal inference. In: Halloran E, Berry D (eds.). Statistical Models in Epidemiology: The Environment and Clinical Trials. Springer-Verlag: New York, 1999, pp 95-134.
33. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 2008; 74: 276-288.
34. Wolf M, Thadhani R. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. Semin Dial 2005; 18: 302-306.
35. Cozzolino M, Ronco C. The impact of paricalcitol on left ventricular hypertrophy. Contrib Nephrol 2011; 171: 161-165.
36. Kovesdy CP, Lu JL, Malakauskas SM, et al. Paricalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial. Am J Kidney Dis 2012; 59(1): 58-66. Epub 2011 Aug 31.PubMed PMID: 21885174
37. Cozzolino M, Mehmeti F, Ciceri P, et al. The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control. Int J Nephrol 2011; 2011: 269060. Epub 2011 Mar 29. PubMed PMID: 21603158; PubMed Central PMCID: PMC3096998
38. Guerrero F, Montes de Oca A, Aguilera-Tejero E, et al. The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol Dial Transplant 2011; 27(6): 2206-12 Epub 2011 Oct 24. PubMed PMID: 22025118.
39. Rodriguez M, Martinez-Moreno JM, Rodriguez-Ortiz ME, et al. Vitamin D and vascular calcification in chronic kidney disease. Kidney Blood Press Res 2011; 34: 261-268.
40. Pritchett Y, Jemiai Y, Chang Y, et al. The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. Clin Trials 2011; 8: 165-174.
41. Thadhani R, Appelbaum E, Chang Y, et al. Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol 2011; 33: 139-149.
42. Thadhani R. Targeted ablation of the vitamin D 1alpha-hydroxylase gene: getting to the heart of the matter. Kidney Int 2008; 74: 141-143.
43. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327-1339.
44. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255.
45. Molnar MZ, Czira ME, Rudas A, et al. Association of the malnutrition-inflammation score with clinical outcomes in kidney transplant recipients. Am J Kidney Dis 2011; 58: 101-108.
46. Noori N, Kovesdy CP, Dukkipati R, et al. Racial and ethnic differences in mortality of hemodialysis patients: role of dietary and nutritional status and inflammation. Am J Nephrol 2011; 33: 157-167.
47. Streja E, Kovesdy CP, Molnar MZ, et al. Role of nutritional status and inflammation in higher survival of African American and Hispanic hemodialysis patients. Am J Kidney Dis 2011; 57: 883-893.
48. Rambod M, Bross R, Zitterkoph J, et al. Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney Dis 2009; 53: 298-309.
49. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551.
50. Cantor T. Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management. Semin Dial 2005; 18: 359-364.